Recombinant Hirudin Medicine Market 2028 Dosage Type, Disease Indication and Geography | The Insight Partners

report image

Recombinant Hirudin Medicine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage Type ( 12000 ATU / mg, 16000 ATU / mg, Others ); Disease Indication ( Heparin-Induced Thrombocytopenia, Unstable Angina, Tumors, Others ) and Geography

Report Code: TIPRE00019586 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming


Recombinant hirudin is a potent thrombin inhibitor originally derived from the medicinal leech. Hirudin acts directly on thrombin rather than through other clotting factors. The mechanism of Hirudin-thrombin appears to be unique. The conversion of fibrinogen into fibrin by the serine protease enzyme thrombin is a major event in the final stages of blood coagulation.


The recombinant hirudin medicine market is driving due to the factors such as increasing number of patients suffering from trauma and rising number of thrombin based diseases. In addition, rising number of healthcare facilities in emerging economies are likely to offer growth opportunities for market players.


The "Recombinant Hirudin Medicine Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of recombinant hirudin medicine market with detailed market segmentation by dosage type and disease indication. The recombinant hirudin medicine market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in recombinant hirudin medicine market and offers key trends and opportunities in the market.


The recombinant hirudin medicine market is segmented on the basis of dosage type and disease indication. Based on dosage type, the market is segmented into 12000 ATU / mg, 16000 ATU / mg, and others. On the basis of disease indication, the market is segmented into heparin-induced thrombocytopenia, unstable angina, tumors, others.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the recombinant hirudin medicine market based on various segments. It also provides market size and forecast estimates from year 2020 to2028with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The recombinant hirudin medicine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting recombinant hirudin medicine market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the recombinant hirudin medicine market in these regions.

Get more information on this report :


The report covers key developments in the recombinant hirudin medicine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from recombinant hirudin medicine market are anticipated to have lucrative growth opportunities in the future with the rising demand for recombinant hirudin medicine in the global market. Below mentioned is the list of few companies engaged in the recombinant hirudin medicine market.

The report also includes the profiles of key players in recombinant hirudin medicine market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

  •  Abbott
  •  Pfizer, Inc.
  •  The Medicines Company
  •  Teva Pharmaceutical Ltd.
  •  Pentapharm
  •  PrimeGene
  •  Aniara Diagnostica
  •  Bioassay Technology Laboratory
  •  Novus Biologicals
  •  Sigma Aldrich (Merck KGaA)

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Abbott
2. Pfizer, Inc.
3. The Medicines Company
4. Teva Pharmaceutical Ltd.
5. Pentapharm
6. PrimeGene
7. Aniara Diagnostica
8. Bioassay Technology Laboratory
9. Novus Biologicals
Sigma Aldrich (Merck KGaA)
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount